The Real Cost of Choosing the Cheapest CDMO: A Total Cost Analysis

Understanding True Total Cost
Why Cheapest Quotes Often Hide Higher Total Costs
A Framework for True Cost Comparison
When Low-Cost CDMOs Make Sense
Red Flags in CDMO Pricing
Making the Right Decision

Mark Jones, COO of Abingdon Health, considers why the lowest-priced lateral flow CDMO often leads to higher total costs in the long term and provides a framework for evaluating the true cost of lateral flow development and manufacturing partnerships.

When evaluating in vitro diagnostics CDMO partners, price naturally plays a significant role in decision-making. Budget constraints are real, and every cent spent on development and lateral flow manufacturing could be used to fund other critical activities. It’s entirely reasonable to consider cost carefully.

However, we’ve observed a troubling pattern: companies that select CDMOs primarily based on having the lowest initial quote frequently end up spending significantly more money and time than companies that select partners based on capability, experience, and realistic project scoping as a whole – even when those partners initially appear to charge higher prices.

This isn’t a moralistic argument about “you get what you pay for.” It’s a practical analysis of how lateral flow test development project costs actually accumulate over time, and why the cheapest initial quote often conceals the most expensive ultimate outcome.

Understanding True Total Cost

When running a lateral flow CDMO cost comparison, most companies naturally focus on the line-item prices: development costs, per-batch manufacturing costs, validation study pricing. These numbers are tangible, comparable, and easy to evaluate.

But the true total cost of a CDMO partnership includes factors that rarely appear on initial quotes:

Timeline Extension Costs
Every month your assay development project extends beyond planned timelines represents opportunity cost. Your competitors are advancing. Your funding is depleting without corresponding progress toward revenue. If you’ve raised money on 18-month development timelines and the project actually takes 30 months, those extra 12 months represent substantial investor dilution and missed market opportunities – costs that dwarf differences in rapid diagnostics contract development pricing.

Rework and Technical Failure Costs
When initial immunoassay development work fails to meet performance requirements or manufacturing quality standards, you’re not just paying for additional development cycles – you’re paying for work that should have been done correctly the first time. Materials are wasted. Validation studies need repeating. Documentation needs revision. These costs accumulate rapidly.

Hidden Change Order Costs
Some IVD CDMOs provide attractively low initial quotes by scoping work narrowly, then recovering margins through change orders for “additional” work that any experienced diagnostics CDMO partner would have (and should have) included in original scoping. You end up paying more overall, but the low initial quote got them in the door.

Regulatory Remediation Costs
If your CDMO’s development and validation work doesn’t generate data suitable for FDA submission, you’ll pay to re-do studies, potentially with a different partner. These costs – both direct expenses and timeline delays – can exceed the entire original development budget.

Lost Opportunity Costs
Perhaps most significantly, if your CDMO partnership ultimately fails and you need to start over with a new service provider, you’ve lost not just the money paid to the first CDMO but all the time competitors used to establish market position. In winner-takes-most diagnostic markets, being second to market with a “me too” in vitro diagnostics product is fundamentally different from being first.

Why Cheapest Quotes Often Hide Higher Total Costs

The lowest-priced CDMOs are rarely intentionally deceptive. But several factors commonly explain why their quotes are lowest – and why those low quotes often lead to higher total project costs:

Inexperience with Realistic Project Scoping
CDMOs without extensive lateral flow immunoassay experience often underestimate the work required to take an assay from concept to a validated, manufacturable product. Their quote reflects basic assumptions and that development will be straightforward, and when reality proves more complex, change orders proliferate. An experienced partner will factor in the complexity of the product to be developed at the outset as best they can.

Lack of Design Control and Quality Systems
Robust design control processes – systematic design reviews, failure mode analyses, verification and validation protocols – cost time and money upfront. Lateral flow CDMO quality issues often emerge when CDMOs trying to minimise costs in a quote will shortcut these processes. The result: technical problems discovered late  – when they’re expensive to fix – rather than early, when they’re manageable.

Limited Regulatory Expertise
FDA submission requirements for in vitro diagnostic medical devices are specific and unforgiving. CDMOs without deep regulatory experience may conduct validation and performance evaluation studies that seem technically sound but don’t generate robust data in formats the FDA requires. Fixing these gaps retroactively costs far more than doing validation correctly in the first place

Resource Allocation Challenges
The cheapest CDMOs often operate on thin margins, which means they must maximise resource utilisation across many projects. Your project may not receive adequate attention or may face delays when competing priorities arise. Timeline extensions translate directly into increased total costs even if per-hour rates seem low.

Manufacturing Scalability Issues
Some CDMOs excel at small-batch development work but lack the equipment, processes, or quality systems necessary for commercial-scale lateral flow test strip manufacturing. If you must switch lateral flow CDMO partners after development, you’re paying for updates in technical transfer, validation, and regulatory preparation – costs that exceed any savings from cheap development.

A Framework for True Cost Comparison

When evaluating IVD CDMO quotes, consider asking questions that reveal the total cost picture rather than just initial price:

Project Scoping:

• “What assumptions are built into this quote? What scenarios would trigger change orders?”
• “What percentage of your similar projects complete within original scope and budget?”
• “Can you provide a detailed work breakdown structure showing what’s included versus excluded?”

These questions reveal whether the quote reflects realistic project understanding or optimistic assumptions.

Quality and Timeline:

• “What is your track record for on-time delivery to original timelines?”
• “How do you handle technical challenges that emerge during development? Are additional optimisation cycles included or extra?”
• “Can you share examples of how your design control processes caught potential problems early?”

These questions assess whether the CDMO has systems in place to avoid expensive late-stage problems.

Regulatory Capability:

• “How many FDA submissions have you supported for products similar to ours?”
• “Can you walk through specifically what validation data FDA will expect for our intended use?”
• “Are your validation study designs and documentation templates proven with FDA, or are we pioneering new approaches?”

These questions determine whether regulatory work will need expensive do-overs.

Total Partnership Cost:

• “What is a typical total project cost from concept through FDA submission and initial commercial manufacturing for projects similar to ours?”
• “Can you provide references from customers at similar stages who can speak to how actual costs compared to initial quotes?”

These questions cut through line-item pricing to understand real total investment required.

When Low-Cost CDMOs Make Sense

This analysis doesn’t mean you should automatically choose the most expensive CDMO. In some scenarios, lower-cost providers genuinely make sense:

If you have strong internal expertise to closely manage the CDMO’s work and catch problems early, you may not need to pay premium prices for the CDMO’s oversight and quality systems.

If you’re conducting early feasibility work with high technical risk and uncertain commercial future, minimising initial investment may be more important than optimising ultimate commercialisation timeline.

If you have realistic expectations about the level of support a lower-cost provider can offer and have backup plans for capabilities they can’t provide, you can manage the relationship appropriately.

The key is making an informed decision based on realistic understanding of what you’re getting – and what you’re not getting – rather than being surprised when cheap quotes lead to expensive problems.

Red Flags in CDMO Pricing

Certain pricing patterns should also prompt greater scrutiny:

Quotes Significantly Below Market Range: If one CDMO’s quote is 30-40% below others for apparently similar scope, that’s data worth investigating. Either they’ve found efficiency others haven’t (possible but rare), or they’ve scoped work more narrowly than you realise.

Vague Scope Definitions: Quotes with ambiguous deliverables (“lateral flow development services”) rather than specific milestones and clear objectives create opportunities for scope creep and change orders.

Lack of Validation Detail: If the quote doesn’t break down validation studies in detail the CDMO may not have thoroughly thought through what validation will actually be required.

Per-Hour Rates Without Hour Estimates: “We charge $X/hour for development work” isn’t a quote – it’s a rate card. Without realistic time-to-deliver estimates for specific deliverables, you can’t evaluate total cost or compare to alternative providers.

Making the Right Decision

The goal isn’t to choose the most expensive CDMO on the theory that high prices equal high quality. The goal is choosing the partner whose capabilities, experience, and project approach align with your project’s actual requirements – and whose pricing reflects realistic understanding of the work involved.

This often means the “right” CDMO has mid-range pricing rather than the cheapest or most expensive. Their quote reflects the work actually required, their processes prevent expensive late-stage problems, and their experience means fewer timeline surprises and change orders.

When evaluating quotes, ask yourself: “If I select this partner and the project takes exactly as long as they estimate, costs exactly what they quote, and delivers exactly what they promise, will I have successfully reached my commercial objectives?”

If the answer requires everything going perfectly with no surprises, you’re probably underestimating true cost and timeline. Successful projects rarely follow perfect plans. They succeed because partners have expertise and systems to handle inevitable challenges efficiently and work with you to realistically resolve issues and achieve your goals.

Choose partners whose experience and capabilities give you confidence that they can navigate the unexpected, not just execute a plan that assumes everything goes smoothly. That confidence is worth paying for – and usually costs less in total than the cheapest alternative that can’t deliver when challenges emerge.

As a fully integrated lateral flow development manufacturing CDMO and CRO with ISO 13485 and ISO 9001 certifications and dual UK/US manufacturing capabilities, our team brings extensive experience in analytical performance studies, clinical trial management, and regulatory strategy for companion diagnostic assay development, STD test development manufacturing, and other in vitro diagnostic solutions. Get in touch with Abingdon Health to explore how our integrated approach can accelerate your path to market access.